Co-Diagnostics 

$1.21
83
-$0.04-3.2% Tuesday 20:00

統計

當日最高
1.24
當日最低
1.18
52週最高
2.23
52週最低
1
成交量
54,697
平均成交量
249,010
市值
44.36M
市盈率
-
股息收益率
-
股息
-

即將到來

收益

7Nov預期
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
下一個
-0.5
-0.4
-0.3
-0.2
預期每股收益
-0.33
實際每股收益
N/A

人們還關注

此列表基於在 Stock Events 上關注 CODX 的人的關注列表。這不是投資建議。

競爭者

這個列表是基於最近市場事件的分析。這不是投資建議。

分析師評級

1.5$平均價格目標
最高估價為 $1.5。
來自過去 6 個月內的 1 個評級。這不是投資建議。
買入
0%
持有
100%
賣出
0%

關於

Health Technology
Biotechnology
Manufacturing
Surgical and Medical Instrument Manufacturing
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Show more...
首席執行官
Dwight Egan
員工
155
國家
US
ISIN
US1897631057

上市公司